Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Table 2

Brain MRI outcomes in the placebo and RTL1000-treated subjects.

Cohort (𝑁)	Baseline-Gadolinium lesion Total count		Day 28—Gadolinium lesion Total count		Day 28—New Gadolinium lesion count		Day 28—New and Enlarging T2 lesion count
	Mean	(min, max)	Mean	(min max)	Mean	(min max)	Mean	(min max)
Placebo (11)	1.6	(0, 9)	1.4	(0, 8)	0.6	(0, 2)	0.5	(0, 3)
2 mg dose (4)	0.8	(0, 2)	0.5	(0, 2)	0.5	(0, 2)	0.8	(0, 2)
6 mg dose (7)	0.9	(0, 4)	0.4	(0, 2)	0.0	(0, 0)	0.1	(0, 1)
20 mg dose (4)	0.0	(0, 0)	0.3	(0, 1)	0.3	(0, 1)	0.3	(0, 1)
60 mg (4)	0.3	(0, 1)	0.3	(0, 1)	0.0	(0, 0)	0.0	(0, 0)
100 mg (1)	1.0	(1, 1)	0.0	(0, 0)	0.0	(0, 0)	0.0	(0, 0)
200 mg (3)	0.0	(0, 0)	0.0	(0, 0)	0.0	(0, 0)	0.0	(0, 0)